Treadwell Therapeutics, a clinical stage, multi-modality biotechnology company developing novel therapeutics for highly aggressive cancers, and Genezen, a cell and gene therapy contract development and manufacturing organization (CDMO), have confirmed a partnership agreement to accelerate the production of T cell receptor (TCR)-based candidates to address unmet needs in cancer patients. The agreement will see Genezen, which focuses on early-phase process development, vector production and ana...